This study focuses on Amyotrophic Lateral Sclerosis, also known as ALS, which is a rare disease that affects the nerve cells in the brain and the spinal cord. This condition causes the muscles to weaken over time. The purpose of the study is to evaluate the efficacy and safety of the drug Usnoflast. Participants in the study will receive either Usnoflast in the form of a capsule or a placebo, which is a substance that looks exactly like the study drug but contains no active medicine.

During the course of the study, the way the body processes the medication, known as pharmacokinetics, and the drug’s effects on the body, known as pharmacodynamics, will be observed. Researchers will also look at NfL, which is a specific protein found in the blood and cerebrospinal fluid—the clear liquid that surrounds the brain and spinal cord—that can indicate nerve cell damage. The study will monitor how the disease progresses and look at how the treatment affects physical functions and survival over a period of time.